Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year phase 3 trial of ALK house dust mite allergy immunotherapy tablet in adults with house dust mite allergic rhinitis
2011-002277-38Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Jul 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of house dust mite allergen extract (dermatophagoides pteronyssinus/dermatophagoides farinae) in allergic rhinitis (AR), perennial rhinitis and house dust mite allergic rhinitis (2 arms), sponsored by ALK-Abelló. Primary endpoint: Average total combined rhinitis score. Started Jul 2011; status: completed.
02
Drugs
house dust mite allergen extract (dermatophagoides pteronyssinus/dermatophagoides farinae)
03
Conditions
allergic rhinitis (AR)perennial rhinitishouse dust mite allergic rhinitis
Beyond the preview
Go deeper on 2011-002277-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002277-38.